Investment Thesis
Zura Bio is a pre-revenue stage biopharmaceutical company with an exceptionally strong balance sheet ($109.4M cash, zero debt, 9.05x current ratio) providing 1.7+ years of operating runway. However, the absence of revenue, -$64.9M annual free cash flow, and -$75.2M operating losses create significant execution risk dependent entirely on clinical/regulatory success rather than financial fundamentals.
Strengths
- Fortress balance sheet with $109.4M cash and zero long-term debt
- Excellent liquidity position (9.05x current ratio, quick ratio) with minimal operational liabilities
- Improving loss trajectory (net loss down 30.9% YoY, indicating operational efficiency gains)
- Minimal capital expenditure burden ($113K) preserving cash for core operations
Risks
- Pre-revenue stage with no visibility into commercial success or path to profitability
- Negative free cash flow of -$64.9M annually, consuming ~59% of available cash reserves annually
- Limited runway of approximately 1.7 years at current burn rate before capital constraints
- Binary outcome dependence on clinical trial success and regulatory approvals; execution risk is clinical, not financial
- Likely shareholder dilution ahead as additional fundraising may be required
Key Metrics to Watch
- Cash burn rate trajectory and quarterly operating cash flow trends
- Revenue recognition milestones and first commercial product launch timing
- Clinical trial phase advancement and regulatory approval status
- Cash runway sustainability and need for secondary capital raises
- Operating expense efficiency as company scales
Financial Metrics
Revenue
N/A
Net Income
-68.7M
EPS (Diluted)
$-1.06
Free Cash Flow
-64.9M
Total Assets
113.9M
Cash
109.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-67.6%
ROA
-60.2%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
9.05x
Quick Ratio
9.05x
Debt/Equity
0.00x
Debt/Assets
10.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-20T00:42:21.122140 |
Data as of: 2025-12-31 |
Powered by Claude AI